Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03860935 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
A Phase 3 study, sponsored by Eidos Therapeutics, a BridgeBio company.
- Completed
- Registry status
- Phase 3
- Development phase
- 632
- Enrollment target
NCT03860935 is a Phase 3 study that has completed, run by Eidos Therapeutics, a BridgeBio company. The registered enrollment target is 632 participants.
The verdict
NCT03860935, a Phase 3 study, has completed, sponsored by Eidos Therapeutics, a BridgeBio company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 632 participants
- Enrollment target
Study Summary
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
Interventions
- DRUG Placebo Oral Tablet
- DRUG acoramidis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 632 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2023-05-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03860935
The ClinicalTrials.gov registry entry for NCT03860935 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 632 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eidos Therapeutics, a BridgeBio company, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03860935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03860935 about?
NCT03860935 is a clinical study titled "Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy". Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
What is the current status of trial NCT03860935?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 632 participants. The study started on 2019-03-19. Estimated completion is 2023-05-11.
What interventions are being tested in trial NCT03860935?
The interventions under investigation include: Placebo Oral Tablet (DRUG), acoramidis (DRUG).
Who is sponsoring clinical trial NCT03860935?
This trial is sponsored by Eidos Therapeutics, a BridgeBio company, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.